TY - JOUR
T1 - Percutaneous closure of a patent foramen ovale
T2 - Single-centre experience using different types of devices and mid-term outcome
AU - Post, Martijn C.
AU - Van Deyk, Kristien
AU - Budts, Werner
PY - 2005/10/1
Y1 - 2005/10/1
N2 - Introduction - Patent foramen ovale (PFO) has been identified as a source of paradoxical embolism and cryptogenic stroke. Low recurrence rates of ischaemic stroke after percutaneous closure have been described. We report our single-centre experience using four different types of devices. Methods - All patients, who underwent a percutaneous PFO closure in the University Hospitals Leuven between February 1999 and December 2003, were included. The primary end point was defined as reoccurrence of stroke, transient ischaemic attack (TIA), or a peripheral thrombo-embolic event. The periprocedural and mid-term complications were reported. Results - One-hundred and twelve patients, mean age 52.1 ± 12.5 years (63 men/49 women), were included in the study. Indications for closure were cryptogenic stroke (91.9%), peripheral embolism (4.5%), obligate right-to-left shunt in Ebstein anomaly (1.8%), platypnoea syndrome or brain abscesses (both 0.9%). The Cardioseal/Starflex® was used in 12, the Amplatzer PFO occluder® in 35, the PFO-Star/CardiaStar® in 64, and the Helex® in one patient. The primary end point occurred in 1.8% for stroke and 2.8% for TIA during a median follow-up of 1.9 years, range 4.9 years. Periprocedural complications were dislocation of the device (0.9%), transient arrhythmias (15.5%), aspiration pneumonia (0.9%), inguinal haematoma (3.6%), and an allergic reaction to medication (1.8%). Mid-term complications were perforation of the device (0.9%), persistent transient arrhythmias (6.3%) and thrombus formation on the device (0.9%). No significant differences in outcome or the occurrence of any type of complication could be documented between the different types of devices. Conclusion - Percutaneous PFO closure seems to be a highly efficient and relatively safe procedure, independent of the type of device used for closure.
AB - Introduction - Patent foramen ovale (PFO) has been identified as a source of paradoxical embolism and cryptogenic stroke. Low recurrence rates of ischaemic stroke after percutaneous closure have been described. We report our single-centre experience using four different types of devices. Methods - All patients, who underwent a percutaneous PFO closure in the University Hospitals Leuven between February 1999 and December 2003, were included. The primary end point was defined as reoccurrence of stroke, transient ischaemic attack (TIA), or a peripheral thrombo-embolic event. The periprocedural and mid-term complications were reported. Results - One-hundred and twelve patients, mean age 52.1 ± 12.5 years (63 men/49 women), were included in the study. Indications for closure were cryptogenic stroke (91.9%), peripheral embolism (4.5%), obligate right-to-left shunt in Ebstein anomaly (1.8%), platypnoea syndrome or brain abscesses (both 0.9%). The Cardioseal/Starflex® was used in 12, the Amplatzer PFO occluder® in 35, the PFO-Star/CardiaStar® in 64, and the Helex® in one patient. The primary end point occurred in 1.8% for stroke and 2.8% for TIA during a median follow-up of 1.9 years, range 4.9 years. Periprocedural complications were dislocation of the device (0.9%), transient arrhythmias (15.5%), aspiration pneumonia (0.9%), inguinal haematoma (3.6%), and an allergic reaction to medication (1.8%). Mid-term complications were perforation of the device (0.9%), persistent transient arrhythmias (6.3%) and thrombus formation on the device (0.9%). No significant differences in outcome or the occurrence of any type of complication could be documented between the different types of devices. Conclusion - Percutaneous PFO closure seems to be a highly efficient and relatively safe procedure, independent of the type of device used for closure.
KW - Cryptogenic stroke
KW - Left-to-right shunt
KW - Potent foramen ovale
UR - http://www.scopus.com/inward/record.url?scp=26444533391&partnerID=8YFLogxK
U2 - 10.2143/AC.60.5.2004973
DO - 10.2143/AC.60.5.2004973
M3 - Article
C2 - 16261783
AN - SCOPUS:26444533391
SN - 0001-5385
VL - 60
SP - 515
EP - 519
JO - Acta Cardiologica
JF - Acta Cardiologica
IS - 5
ER -